NCT01890135View on ClinicalTrials.gov

Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Peripheral Arterial DiseaseIntermittent Claudication
Interventions
DRUG

Zibotentan (ZD4054)

10 mg

DRUG

placebo

randomized double blind

Trial Locations (1)

22908

University Of Virginia Health System, Charlottesville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Virginia

OTHER

NCT01890135 - Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication | Biotech Hunter | Biotech Hunter